Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M
Record ID 32013000629
English
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hta.ac.uk/erg/supplements/supplement1401.pdf#nameddest=article07
URL for additional information:
http://www.hta.ac.uk/1875
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Cost-Benefit Analysis
- Disease Progression
- Models, Economic
- Pemetrexed
- Quality-Adjusted Life Years
- Antimetabolites, Antineoplastic
- Carboplatin
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Deoxycytidine
- Glutamates
- Guanine
- Immunosuppressive Agents
- Lung Neoplasms
- Radiation-Sensitizing Agents
- Taxoids
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.